Mylan 1Q Revenues: $2.7 billion (-1%) 1Q Earnings: $87.1 million (+32%) Comments: Sales in the North America segment were $985.3 million, down 19% primarily due to a combined decrease in the sales of branded products, including EpiPen Auto-Injector, loss of exclusivity of olmesartan and olmesartan HCTZ and the prior year divestiture of certain contract manufacturing assets. Sales in Europe were $146.4 million, up 16% in the quarter, primarily the result of the favorable impact of foreign curr...